Selpercatinib or Chemotherapy in RET Fusion-Positive NSCLC. Reply
| Errataetall: |
CommentOn: N Engl J Med. 2023 Nov 16;389(20):1839-1850. - PMID 37870973 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:390 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 390(2024), 4 vom: 25. Jan., Seite 381-382 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhou, Caicun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 25.01.2024 Date Revised 25.01.2024 published: Print CommentOn: N Engl J Med. 2023 Nov 16;389(20):1839-1850. - PMID 37870973 Citation Status MEDLINE |
|---|
| doi: |
10.1056/NEJMc2314327 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367560836 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367560836 | ||
| 003 | DE-627 | ||
| 005 | 20240126232154.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240124s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMc2314327 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1271.xml |
| 035 | |a (DE-627)NLM367560836 | ||
| 035 | |a (NLM)38265654 | ||
| 035 | |a (PII)10.1056/NEJMc2314327#sa2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhou, Caicun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Selpercatinib or Chemotherapy in RET Fusion-Positive NSCLC. Reply |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.01.2024 | ||
| 500 | |a Date Revised 25.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: N Engl J Med. 2023 Nov 16;389(20):1839-1850. - PMID 37870973 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a pembrolizumab |2 NLM | |
| 650 | 7 | |a DPT0O3T46P |2 NLM | |
| 650 | 7 | |a selpercatinib |2 NLM | |
| 650 | 7 | |a CEGM9YBNGD |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Pyrazoles |2 NLM | |
| 650 | 7 | |a Pyridines |2 NLM | |
| 650 | 7 | |a RET protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins c-ret |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Solomon, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Pérol, Maurice |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 390(2024), 4 vom: 25. Jan., Seite 381-382 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
| 773 | 1 | 8 | |g volume:390 |g year:2024 |g number:4 |g day:25 |g month:01 |g pages:381-382 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMc2314327 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 390 |j 2024 |e 4 |b 25 |c 01 |h 381-382 | ||